Original from: Diasorin
Diasorin (FTSE MIB: DIA) today announced the signing of a supplier agreement with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services based in and serving the United States.
Under the terms of the agreement, Diasorin will install 24 LIAISON PLEX systems in 8 Quest Diagnostics laboratories in the U.S. Each LIAISON PLEX® system has 6 chambers allowing for high-volume testing.
Diasorin expects to supply its LIAISON PLEX Respiratory Panel to Quest Diagnostics to serve demand for molecular testing during the upcoming flu season.
This agreement marks a pivotal milestone in Diasorin¡¯s multiplexing strategy and underscores the increasing recognition of the LIAISON PLEX platform¡¯s advanced technical capabilities, usability, and diagnostic accuracy.
¡°We are proud to see our technology embraced by one of the largest laboratory networks in the U.S.,¡± said Angelo Rago, President of Luminex. ¡°This agreement validates the value of our multiplexing platform in supporting laboratories to deliver more informed diagnostic insights while maintaining operational simplicity.¡±
